TAP, Shire ink deal to market Lialda
LAKE FOREST, Ill., and WAYNE, Pa. TAP Pharmaceutical Products and Shire have signed a three-year agreement to co-promote the mild-to-moderate ulcerative colitis drug Lialda, according to published reports.
The agreement will add more than 500 additional sales representatives from TAP to Shire’s 120-person sales force, which markets the drug primarily to gastroenterologists.
“With the added expertise of the TAP team, we’ll be able to reach more GI specialists as well as primary-care providers with messages about Lialda,” said Mike Yasick, senior vice president of Shire’s gastrointestinal business unit.
The TAP sales force will begin promoting Lialda to specialists and certain primary-care physicians in April 2008.
Sugar may be helpful for those with diabetes and obesity
BALTIMORE Researchers have found a new treatment that may be helpful in aiding those with diabetes and obesity, and it is most unusually a sugar.
The sugar is known as tagatose, which, according to published reports, is used in Europe to sweeten candy or orange juice. It is a naturally occurring version of fructose and is derived from the dairy byproduct whey. Tagatose has been shown to stop blood sugar spiking and is currently undergoing a one-year clinical trial to see if is, in fact, helpful in managing diabetes and weight-loss.
According to the American Diabetes Association, about 20.8 million people are diabetic and 9 out of 10 diabetics with Type 2 are overweight. Many researchers, such as Phillip Levin, an endocrinologist and director of diabetes center at Mercy, hope that tagatose can become a diet drug for patients experiencing obesity, one of the leading causes of diabetes. According to Levin, “Tagatose could be another tool for damage control. A lot of dealing with Type 2 diabetes is damage control.”
Other studies have shown that tagatose, if ingested before meals, would stop the rise in blood sugar, because it is absorbed poorly and therefore affects the way the sugar is stored. According to published reports, tagatose is said to be possibly the only diabetes drug that could raise good cholesterol and act as a cell-protecting antioxidant.
FDA to take a closer look at Singulair
WASHINGTON The Food and Drug Administration has warned health care professionals that it is investigating possible side effects in the asthma drug Singulair.
Possible side effects of the drug, a Merck product, include behavior/mood changes, suicidality and suicide.
The agency will need up to nine months to complete ongoing evaluations about the safety of the drug.
“Patients should not stop taking Singulair before talking to their doctor if they have questions about this new information,” the FDA said. “Until further information is available, healthcare professionals and caregivers should monitor patients taking Singulair for suicidality and changes in behavior and mood.”